| ²é¿´: 531 | »Ø¸´: 3 | ||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | ||
yin198716гæ (ÕýʽдÊÖ)
|
[ÇóÖú]
ÇóÖú ·Òë
|
|
|
1 A recent report demonstrated that chronic Dll4 blockade induced vascular proliferation in liver of mice, rats, and monkeys with associated hepatocellular changes, as well as the development of subcutaneous vascular lesions in rats, referred to as neoplasia. 2 It will be important to assess whether similar pathological changes are observed with doses of anti-Dll4 antibody that are clinically relevant. |
» ²ÂÄãϲ»¶
Ò»Ö¾Ô¸ ½ÄÏ´óѧ 085602 »¯¹¤×¨Ë¶ 338·ÖÇóµ÷¼Á
ÒѾÓÐ14È˻ظ´
312Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
070300»¯Ñ§Ñ§Ë¶311·ÖÇóµ÷¼Á
ÒѾÓÐ13È˻ظ´
²ÄÁϵ÷¼Á
ÒѾÓÐ9È˻ظ´
Ò»Ö¾Ô¸ºÓ±±¹¤Òµ´óѧ²ÄÁϹ¤³Ì£¬³õÊÔ344Çóר˶µ÷¼Á
ÒѾÓÐ4È˻ظ´
²ÄÁÏר˶322
ÒѾÓÐ8È˻ظ´
Ò»Ö¾Ô¸211£¬»¯Ñ§Ñ§Ë¶£¬310·Ö£¬±¾¿ÆÖصãË«·Ç£¬Çóµ÷¼Á
ÒѾÓÐ13È˻ظ´
0703»¯Ñ§
ÒѾÓÐ14È˻ظ´
µ÷¼Á Ò»Ö¾Ô¸¼ªÁÖ´óѧ357·Ö
ÒѾÓÐ3È˻ظ´
»¯Ñ§µ÷¼Á
ÒѾÓÐ18È˻ظ´

¡ï ¡ï
°®ÓëÓêÏÂ: ½ð±Ò+1 2013-01-11 22:23:59
phu_grassman: ½ð±Ò+1, thanks 2013-01-12 12:42:43
°®ÓëÓêÏÂ: ½ð±Ò+1 2013-01-11 22:23:59
phu_grassman: ½ð±Ò+1, thanks 2013-01-12 12:42:43
|
±¾ÌûÄÚÈݱ»ÆÁ±Î |
2Â¥2013-01-11 15:59:32
phu_grassman: what are talking about here? 2013-01-12 12:42:28
|
±¾ÌûÄÚÈݱ»ÆÁ±Î |
3Â¥2013-01-11 16:00:20
nwsuafliu
ľ³æ (ÖøÃûдÊÖ)
- ·ÒëEPI: 144
- Ó¦Öú: 42 (СѧÉú)
- ½ð±Ò: 2406.9
- É¢½ð: 1449
- ºì»¨: 18
- Ìû×Ó: 1437
- ÔÚÏß: 315.6Сʱ
- ³æºÅ: 136928
- ×¢²á: 2005-12-17
- רҵ: ×÷Îï·Ö×ÓÓýÖÖ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï
°®ÓëÓêÏÂ: ½ð±Ò+1 2013-01-11 22:24:06
phu_grassman: ½ð±Ò+3, thanks for your time. You\\\'ve done a good job. 2013-01-12 12:42:13
sltmac: ½ð±Ò+5, ·ÒëEPI+1, Thank you 2013-03-10 10:01:02
°®ÓëÓêÏÂ: ½ð±Ò+1 2013-01-11 22:24:06
phu_grassman: ½ð±Ò+3, thanks for your time. You\\\'ve done a good job. 2013-01-12 12:42:13
sltmac: ½ð±Ò+5, ·ÒëEPI+1, Thank you 2013-03-10 10:01:02
|
1 A recent report demonstrated that chronic Dll4 blockade induced vascular proliferation in liver of mice, rats, and monkeys with associated hepatocellular changes, as well as the development of subcutaneous vascular lesions in rats, referred to as neoplasia. ×î½üÒ»·Ý±¨¸æ±íÃ÷£¬ÂýÐÔDll4×è¶ÏÄܹ»ÓÕ·¢Ð¡Êó¡¢´óÊóºÍºï×Ó¸ÎѪ¹ÜÔöÉú£¬²¢°éËæ¸Îϸ°û¸Ä±ä£¬ÒÔ¼°´óÊóƤÏÂѪ¹Ü²¡±äµÄ·¢Õ¹£¨³ÆÎªÁö£©¡£ 2 It will be important to assess whether similar pathological changes are observed with doses of anti-Dll4 antibody that are clinically relevant. ÔÚ²ÉÓÃÁÙ´²Ïà¹Ø¼ÁÁ¿µÄ¿¹Dll4¿¹ÌåÌõ¼þÏ£¬¿¼²ìÄÜ·ñ¹Û²ìµ½ÀàËÆ²¡Àí±ä»¯½«Ê®·ÖÖØÒª¡£ |

4Â¥2013-01-11 16:18:30














»Ø¸´´ËÂ¥
10